Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome
2007

Fatal Complications After Oesophagectomy Linked to Neoadjuvant Therapy

Sample size: 1 publication Evidence: low

Author Information

Author(s): Michael Knauer, Anton Haid, Karlheinz Ammann, Alois Lang, Felix Offner, Martina Türtscher, Peter Cerkl, Etienne Wenzl

Primary Institution: General Hospital of Feldkirch, Academic Teaching Hospital, Feldkirch, Austria

Hypothesis

What is the role of cetuximab in the complications following oesophagectomy?

Conclusion

The study highlights a potentially fatal combination of complications after oesophagectomy, with an unclear role of cetuximab in these outcomes.

Supporting Evidence

  • The patient developed severe complications after receiving cetuximab as part of neoadjuvant therapy.
  • The complications included gas exchange dysfunction and circulation instability.
  • The study emphasizes the need for careful monitoring of complications in patients receiving targeted therapies.

Takeaway

A patient died after surgery for esophageal cancer, and doctors are unsure if a drug called cetuximab caused some of the problems.

Methodology

Case report detailing the patient's treatment and complications following oesophagectomy.

Potential Biases

Potential bias in linking complications directly to cetuximab without definitive evidence.

Limitations

The exact contribution of cetuximab to the complications could not be determined.

Participant Demographics

A 52-year-old man diagnosed with squamous-cell esophageal cancer.

Digital Object Identifier (DOI)

10.1186/1477-7819-5-114

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication